Arbutus biopharma corporation announces impairment charges for the third quarter ended september 30, 2019

Arbutus biopharma corporation announced impairment charges for the third quarter ended september 30, 2019. for the quarter, the company reported impairment of intangible assets of $43.8 million compared to $14.8 million a year ago. impairment of goodwill was $22.5 million.
ABUS Ratings Summary
ABUS Quant Ranking